Bile Duct Cancer Treatment Market Demand, Recent Developments, Company Profile Analysis, and Growth Opportunities Forecast Report 2022-2029

June 24 19:03 2022
Bile Duct Cancer Treatment Market Demand, Recent Developments, Company Profile Analysis, and Growth Opportunities Forecast Report 2022-2029
Bile Duct Cancer Treatment Market | DataM Intelligence
Bile Duct Cancer Treatment Market major companies include ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Incyte Corporation, Celgene Corp, Bayer AG, Boston Scientific Corporation, and major companies profiled in the final report

Bile Duct Cancer Treatment Market Outlook:

According to the research report published by the DataM Intelligence, the global Bile Duct Cancer Treatment Market size is projected to reach USD billion by the end of 2029, with growth at a CAGR of 9.2% during the forecast period 2022-2029.

Bile Duct Cancer, also known as Cholangiocarcinoma, forms in the slender tubes (bile ducts) that carry the digestive fluid bile. Bile ducts connect the liver to the gallbladder and small intestine. It occurs mainly in people older than age 50, though it can occur at any age. The particular causes of bile duct cancer are unknown.

However, a few factors responsible for developing bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection with liver fluke’s parasite that causes mainly infection in the bile duct leading to cancer, and exposure to harmful chemicals and toxins. Major symptoms associated with bile duct cancer include jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever. Bile duct cancer is treated by Chemotherapy, Surgery, Radiation therapy, Targeted therapy, and Others.

Report Statistics:



Market CAGR


Largest Market

North America

Fastest Growing Market

Asia Pacific

Market Segmentation

By Cancer Type, By Treatment Type, By End-users, and By Region

Report Covered

Methodology and Scope, Industry Analysis, COVID-19 Analysis, Regional Analysis, Competitive Landscape, and Company Profile Analysis.

The global Bile Duct Cancer (Cholangiocarcinoma) Treatment growth is driven by the increasing prevalence of bile duct cancers worldwide, increasing geriatric population, changing lifestyles and increasing smoking habits; rising investment in research and development activities are the major factors driving the market.

Regional Share Insights:

Bile Duct Cancer, also known as Cholangiocarcinoma, is spreading widely in Southeast Asia. The high consumption of raw fish in the Asia-Pacific (APAC) region drives the incidence of liver fluke infections, thereby stimulating bile duct cancer. Increased industrialization is also attributed to the growth in the APAC region as exposure to harmful printing chemicals are high among industrial workers in countries such as China, Japan, and India. For instance, Eisai Co., Ltd- A  Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion.

North America holds the second-largest market in the global bile duct cancer market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and photodynamic therapy methods, the total availability of advanced technological tools, FDA approval of new drugs, and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

Download Sample Brochure @

Impact of COVID-19 on the industry:

The COVID-19 pandemic has negatively impacted healthcare systems globally and in the vulvar Cancer market. The Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.

Market Segmentation Insights:

Based on the Cancer Type, the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented into Intrahepatic bile duct cancer and Extrahepatic bile duct cancer. Intrahepatic bile duct cancer occurs in the bile ducts within the liver and is sometimes classified as a type of liver cancer. This type makes up 5% to 10% of cases.

Extrahepatic bile duct cancer: This type occurs more often and is more treatable and might form in one of two areas. The hilum region, where your left and right bile ducts come together to form the common hepatic duct. It is called perihilar cancer. More than 60% of the plethora of bile duct cancers fall in the category of perihilar bile duct cancers. The distal Region, where your common bile duct passes through the pancreas. This is called distal cancer.

Chemotherapy (chemo) is treatment with cancer-killing drugs usually given into a vein (IV) or taken by mouth. These drugs enter the bloodstream and reach all areas of the body, making this a helpful treatment for some cancers that have spread to organs beyond the bile duct. As the drugs reach all the areas of the body, this is known as a systemic treatment. The drugs used in chemo are 5-fluorouracil, gemcitabine, capecitabine, oxaliplatin, cisplatin, and combined drug treatment. Factors such as the availability of a wide range of chemotherapeutics agents for the treatment of bile duct cancer and ongoing innovative research combinations work on the improvement of chemotherapy by studying new drugs and new combinations of drugs through clinical trials are anticipated to boost the market growth of the chemotherapy segment during the forecast period.

Due to the growing patient population, the hospital segment held the largest market share. This is mainly due to the increasing number of patients suffering from conditions treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment. Also, the medications can be administrated intravenously, and surgery is done under the supervision of medical practitioners at these locations.

Make an Inquire before purchasing the full report @

Competitive Landscape and Major Companies Profiled:

The Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market is quite competitive with some key competitors like ConMed Corporation, Bristol-Myers Squibb, Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Incyte Corporation, Celgene Corp, Bayer AG, and Boston Scientific Corporation. The major players adopt several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market’s growth globally. For instance, Incyte Corporation-A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma.

Market Segmentation:

By Cancer Type:

Intrahepatic bile duct cancer

Extrahepatic bile duct cancer


By Treatment Type:


Photodynamic therapy


Radiation therapy


By End-users:



Cancer research institutes


The Full Report has the below insights.

  1. The report offers a comprehensive evaluation of the market in terms of Market Value (US$) and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-2021), and verifiable projections about market size during the forecast period (2022-2029).
  2. Visualize the composition of the Bile Duct Cancer Treatment Market Segmentation By Cancer Type, By Treatment Type, By End-user, and Region, highlighting the key commercial assets and players.
  3. Identify commercial opportunities in the Market by analyzing trends and co-development deals.
  4. The report also covers data insights on various industry forces such as porter’s five forces, regulations in each country, reimbursement scenario, technological advancements, PEST analysis, and pricing analysis.
  5. Excel data sheet with thousands of Market-level 4/5 segmentation data points.
  6. PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. 
  7. Product mapping in excel for the key product of all major market players
  8. The report will provide access to approximately 50+ market data tables, 40+ figures, and close to 180 pages. 

Additional Benefits Post Purchase:

  1. Unlimited Analyst support for a period of 1 year.
  2. Any query regarding the scope offered will be addressed within 24- 48 hours.
  3. An excel sheet with market numbers will be provided separately

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States